Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

44.6K
Overview
44.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Full-Length Next-Generation Sequencing of 11 HLA Loci of More Than 1000 Individuals From Clinical Cohorts in East and West Africa.

HLA·2026
Same author

Expert Recommendations to Strengthen Chikungunya Outbreak Surveillance and Reporting for Traveler Health Protection.

The American journal of tropical medicine and hygiene·2026
Same author

Influence of Gut Microbiota on Immune Responses and Protection in Volunteers Receiving the Live Attenuated Oral ETEC Vaccine ACE257 followed by Virulent ETEC H10407 Challenge.

Research square·2026
Same author

The case for evaluation of double mutant heat-labile toxin as an adjuvant to improve oral cholera vaccine immunogenicity.

Frontiers in immunology·2026
Same author

Economic evaluation of combination vaccines: Enabling a more comprehensive assessment of their benefits and challenges.

Vaccine·2026
Same author

Accelerating research and development of new vaccines against tuberculosis: 5-year progress on the global roadmap.

The Lancet. Infectious diseases·2026

Related Experiment Video

Updated: Jul 13, 2025

A High-throughput Shigella-specific Bactericidal Assay
06:11

A High-throughput Shigella-specific Bactericidal Assay

Published on: February 27, 2019

11.8K

Vaccine value profile for Shigella.

William P Hausdorff1, John D Anderson2, Karoun H Bagamian3

  • 1Center for Vaccine Innovation and Access, PATH, 455 Massachusetts Ave NW, Washington, DC 20001, USA; Faculty of Medicine, Université de Bruxelles, Brussels 1070, Belgium.

Vaccine
|October 12, 2023
PubMed
Summary
This summary is machine-generated.

Developing a Shigella vaccine is a global health priority, especially for children in low- and middle-income countries (LMICs). This Vaccine Value Profile assesses current data to guide the development of effective Shigella vaccines.

Keywords:
Bacterial enteric diseaseDiarrheal diseaseDysenteryImmunization

More Related Videos

Author Spotlight: Advancements in Understanding and Combatting Shigella Infections
04:56

Author Spotlight: Advancements in Understanding and Combatting Shigella Infections

Published on: February 9, 2024

979
Imaging Ca2+ Responses During Shigella Infection of Epithelial Cells
08:56

Imaging Ca2+ Responses During Shigella Infection of Epithelial Cells

Published on: May 24, 2018

5.6K

Related Experiment Videos

Last Updated: Jul 13, 2025

A High-throughput Shigella-specific Bactericidal Assay
06:11

A High-throughput Shigella-specific Bactericidal Assay

Published on: February 27, 2019

11.8K
Author Spotlight: Advancements in Understanding and Combatting Shigella Infections
04:56

Author Spotlight: Advancements in Understanding and Combatting Shigella Infections

Published on: February 9, 2024

979
Imaging Ca2+ Responses During Shigella Infection of Epithelial Cells
08:56

Imaging Ca2+ Responses During Shigella Infection of Epithelial Cells

Published on: May 24, 2018

5.6K

Area of Science:

  • Infectious Diseases
  • Vaccinology
  • Public Health

Background:

  • Shigella is a major cause of bacterial diarrhea and mortality, particularly in children under five in LMICs.
  • Increasing antibiotic resistance in Shigella necessitates urgent vaccine development.
  • The World Health Organization (WHO) prioritizes a safe, effective, and affordable Shigella vaccine.

Purpose of the Study:

  • To provide a holistic assessment of available data for Shigella vaccine candidates.
  • To inform the potential public health, economic, and societal value of pipeline Shigella vaccines.
  • To identify current research and knowledge gaps in Shigella vaccine development.

Main Methods:

  • Development of a Vaccine Value Profile (VVP) for Shigella.
  • Utilized existing and publicly available information.
  • Involved a working group of subject matter experts from diverse organizations.

Main Results:

  • Advanced vaccine candidates include multivalent parenteral formulations in Phase 2/3 clinical trials.
  • Emerging formulations involve O-antigen-polysaccharide protein conjugates or detoxified outer membrane vesicles.
  • Earlier-stage candidates explore broader antigen delivery via parenteral and oral routes.

Conclusions:

  • Shigella vaccines are crucial for reducing disease burden, antibiotic use, and antimicrobial resistance.
  • Pipeline vaccines are being evaluated against WHO Preferred Product Characteristics for infant immunization.
  • The VVP highlights the need for continued research to address knowledge gaps and maximize vaccine value.